S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis

Clinical Cancer Research

Volumn 18, Issue 16, 2012, Pages 4356-4364

  Arumugam, Thiruvengadam ^a   Ramachandran, Vijaya ^a   Gomez, Sobeyda B ^a   Schmidt, Ann M ^b   Logsdon, Craig D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTAGONIST PEPTIDE; CALVASCULIN; GLUTAMYLLEUCYLLYSYLVALYLLEUCYLMETHIONYLGLUTAMYLLYSYLGLUTAMYLLEUCINE; GLYCYLLYSYLASPARTYLLYSYLASPARTYLALANYLVALYLASPARTYLLYSYLLEUCYLLEUCYLLYSYLASPARTIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; LYSYLGLUTAMYLLEUCYLPROLYLGLYCYLPHENYLALANYLLEUCYLGLUTAMINYLSERYLGLYCYLLYSYLASPARTYLLYSYLASPARTIC ACID; PROTEIN INHIBITOR; PROTEIN S 100; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CANCER INHIBITION; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PANCREAS; PANCREAS ADENOCARCINOMA; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CALCIUM-BINDING PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; HMGB1 PROTEIN; HUMANS; LIGANDS; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; NF-KAPPA B; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN BINDING; RECEPTORS, IMMUNOLOGIC; S100 PROTEINS;

EID: 84865085648     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0221     Document Type: Article

References (27)

1. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med 2007;7:777-89.
2. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005;15:16R-28R.
3. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005;83:876-86.
4. Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs 2006;7:985-91.
5. Arumugam T, Logsdon CD. S100P: a novel therapeutic target for cancer. Amino Acids 2011;41:893-9.
6. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-60.
7. Abe R, Shimizu T, Sugawara H, Watanabe H, Nakamura H. Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol 2004;122:461-7.
8. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Can Res 2002;62:4805-11.
9. Arumugam T, Ramachandran V, Logsdon CD. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 2006;98:1806-18.
10. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002;196:163-70.
11. Wear-Maggitti K, Lee J, Conejero A, Schmidt AM, Grant R, Breitbart A. Use of topical sRAGE in diabetic wounds increases neovascularization and granulation tissue formation. Ann Plast Surg 2004;52:519-21.
12. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002;106:2827-35.
13. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003;9:907-13.
14. Arumugam T, Simeone DM, Schmidt AM, Logsdon CD. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem 2004;279:5059-65.
15. Arumugam T, Simeone DM, Van Golen K, Logsdon CD. S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res 2005;11:5356-64.
16. Heizmann CW, Ackermann GE, Galichet A. Pathologies involving the S100 proteins and RAGE. Subcell Biochem 2007;45:93-138.
17. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-55.
18. Chavakis T, Bierhaus A, Schneider D, Linn T, Nagashima K, Morser J, et al. The pattern recognition receptor (RAGE) is a counter receptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003;198:1507-15.
19. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis, but not the adaptive immune response. J Clin Invest 2004;113:1641-50.
20. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell 2002;111:927-30.
21. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119-27.
22. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;4:301-10.
23. Arlt A, Vorndamm J, Breitenbroich M, Fölsch UR, Kalthoff H, Schmidt WE, et al. Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 2001;20:859-68.
24. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB-1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010;28:367-88.
25. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006;290:C917-24.
26. Boye K, Maelandsmo GM. S100A4 and metastasis: a small actor playing many roles. Am J Pathol 2010;176:528-35.
27. Mahon PC, Baril P, Bhakta V, Chelala C, Caulee K, Harada T, et al. S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res 2007;67:6786-95.